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SUMMARY.-Of 141 suspected cases of Burkitt's lymphoma referred from all
over Ghana between November 1965 andJune30,1969, the diagnosis of Burkitt's
lymphoma was confirmed histologically in 60. This report deals with survival
of all 50 treated and evaluable cases. The overall estimated long term survival
rate was 38.5% calculated actuarially. It was 63-2% for Stage I (10 of 18);
20-0% for Stage II (2 of 10); and254% for Stages III and IV combined (3 of22),
thus confirming the value ofstaging as arough guide toprognosis. Six Stage I
patients who died all had large tumors. These results have been compared
with a similar studyby Morrow et al. (1967) from Uganda.
INspite oftheproblems ofkeeping track ofpatients in thedeveloping countries
in Africa, a few centers working on Burkitt's lymphoma have managed to obtain
adequate follow-up information on the majority oftheir patients (Clifford, 1966;
Morrow et al., 1967; Ngu, 1968). However, the Burkitt's Tumor Project in the
Korle Bu Teaching Hospital, Accra, has certain unique advantages. Nearly all
proven or suspected cases in Ghana are referred to the Project for diagnosis,
treatment, and after-care. Information on incidence, epidemiology, pathology,
treatment, and prognosis is correspondingly comprehens'lve, centrahzed, and
readily available. The present communication reviews the survival of patients
with Burkitt'slymphoma in Ghana. Comparablereports have come from Nairobi
(Clifford, 1966; Pike, 1966), Kampala (Morrow et al., 1967), and lbadan (Ngu,
1968).
PATIENTS AND METHODS
The Burkitt's Tumor Project in Ghana was established in November 1965.
By June 30, 1969 a total of 141 suspected cases had been referred to the Project. Specimens of biopsy material, ascitic fluid, frozen serum, and pathology shdes
from many of the patients were sent to the National Cancer Institute of the
National Institutes ofHealth, USA, forpathologic review andspecial studies such
as electron microscopy, cytology, tissue culture andvirology. The diagnosis of Burkitt's lymphoma was confirmed histologicany in 60 of the
141 patients. Biopsy material was used in 53, ascitic fluid only in two, autopsy material in three and cerebrospinal fluid only in two cases. All 60 cases were
reviewed andanalyzedby age, sex, clinicalstage, and survival. Theremaining 81
patients did not have histologically confirmed Burkitt's tumor and the final
histological diagnoses covered a wide range ofpathology.
Requests for reprints should be addressed to: Burkitt's Tumor Project, P.O. Box 194, Accra, Ghana.A Survival rate was calculated for 50 patients. Seven patients who died in
hospital beforereceiving treatment and three whodiedwithintwodaysofbeginning
treatment were excluded from the survival analysis. The survival time was
calculated as weeks from date of initial treatment until the patient died or was
last seen, through December 31, 1969. Patients who lived .52 weeks and over
were considered
" long-term survivors ".
STAGING AND TREATMENT
The staging used was that described by Morrow et al. (1967), and later modified
by Ziegler et al. (1969).
Stage 1: Single facial tumor mass.
Stage 11: Two or more separate facial tumor masses.
Stage III: Lymphoma involving any intrathoracic or intra-abdominal areas
or osseous tumors (excluding facial bones).
Stage IV: Lymphoma involving the central nervous system or bone marrow.
Lumbar punctures were performed for cytological examination routinely
beginning in March 1969. Before that date, this procedure was done only when
clinically indicated.
Prior to November 1967, patients were treated NN-ith a variety of cytotoxic
drugs. Subsequently a treatment protocol was adopted under which allpatients
were treated initially with cyclophosphamide. Second line drugs used for relapse
and/or non-response were vincristine, methotrexate, and cytosine arabinoside.
The place of surgery wasprimarily forobtainingbiopsy material fordiagnosis.
Unilateral or bilateral oophorectomy was performed in seven patients. One
patient had enucleation of a destroyed eye, another had a mass of an eyelid
excised, and a third underwent spinal cord decompression.
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FiG. I.--Age distribution in 60 patients, laboratory confirmed Burkitt's.BURKMIS LYMPHOMA IN GHANA 481
PATIENT FOLLOW-UP
-Afterdischarge from hospital, each patient was visited in his home by a social
worker. Once every 3months, afoRow-up clinic wa-sheldintheKorle BuTeac
Hospital. Accra. AD surviving cases were brought down from their homes to be
reviewed jointly by the members of the Project. Patients who could not or
failed to attend thefollow-up clinics were revisitedby a social worker and informa-
tionconcerningtheirwelfareobtained.
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FIG.2.--Survivalcurve 50treatedcases--allstages. AdmittedJune30,1969,and
foHowed through to December 31, 1969.
RESULTS
Fig. I is the histogmm of the age incidence of the 60 histologicaBy proven
cases of Burkitt's lvmphoma considered in this study. The age distribution
agrees closelv with that reported elsewhere (Burkitt and O'Conor, 1961; Haddow,
A. J.7 1964). Only two patients were under four years of age and three other
were post pubertal. The sex ratio was 1-6 : I in favor ofboys (37 boys and 2-0
girls).
T-kBLE I.-Low Term Surtitnl andStage, at Pre8entation
Estimatedlong
term survival
No. of at-risk '.%'o. oflong iterm ratet
Stage patients survivors* ( /0)
18 10 63-2
H 10 2 20
-0
M and IV 22 3 2,5-4
AD patientb- 50 15 38-5
Calculated firom date treatment begun.
t CalculgLted iLctuarigLllv.
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FIG. 3.-Survival curves-Stages I, III, III and IV.
Table I showsthedistributionofthe 50treatedandevaluablepatientsaccording
to clinical stage (cf. Morrow et al., 1967). More than half of the patients had
localized disease (Stages I and 11). Also shown is the number of
" long-term
survivors
" by stage and estimated long term survival rate. Table 11 shows the
survivaltimeinweeksby agegroups andbyclinlicalstageofdiseaseatpresentation.
The survival curve for the 50 treated cases is shown in Fig. 2. In this series,
the overall long term survival rate for treated cases was 38-5%. Survival was
also calculatedb-y clinical stage andby age groups. Fig. 3 shows survival accord-
ing to clinical stage and demonstrates the much better prognosis of Stage I
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FiG. 4.-Survival curves by age groups.BURKITT5S LYMPHOMA IN GHANA 483
TABLE II.-Survival Times of 50 Patients in Weeks
Age at
presentation
in years
0-4
.1 9 0-
10-14
15-19
Total
Stage at presentation
I
Total
"I number of
patients
6
29
12
3
50
Stage I
160*, 39
191*, 19, 150*,
152*, 54, 102*
41, 74*, 74*,
29*, 48*
175*, 19, 28*,
71*
29
18 patients
Stage II
6, 9, 58*
14, 26, 10, 9, 12
Stages III and IV
38
9, 36, 19, 6, 44,
21, 123*, 109*,
4, 27, 44*, 11,
30*
12, 104*, 13, 6,
23*, 23*
12, 6
22 patients
142*, 11
10 patients
* -- Patient still alive December 31, 1969.
patients. However, there is no demonstrable difference in survival between
Stage 11 and Stages III and IV patients. Fig. 4 shows survival curves by age
groups. No marked differences in the age groupsanalyzed are observed.
TABLE III.-Stage One Patients who Died
Size of
tumor on
admission
Very large
Survival
time in
weeks
20
Code Age Site of
number and sex primary
K-28 . 7F . L mandible
(orbit-ve)
K-45 . 2 M . R orbit
K-54 . 7M . L orbit
K-68 . 11 M . L maxilla and
orbit
K-75 . 8M R maxillary
antrum
Comment
. Response to chemotherapy
Nil
. Large
. Large
. Very large
. Very large
39 Enucleation ofdestroyed R eye.
Recurrence in R jaw, 4 inch
diameter
54 Destroyed eye enucleated.
Recurrence in R mandible and
in R upper eyelid
19 Partial response. Rapid
recurrence. Fast down-hill
course
41 Good initial response.
Recurred; CNS involved:
pathological fracture
29 Had surgical excision first.
Response of residual lesion
to chemotherapy: Nil
K-103 . 18 F . Cervical lymph
. Very large
nodes
(orbit-ve)
Six Stage I patients died, and are summarized in Table 111. They were aged
2 . 7) 7 . 8 . II , and 18 years. There were four boys and two girls. The orbit was
involvedgrossly inthree, maxillary antrum in one, cervicallymph nodesprimarily
in one, and the mandible in one. In the latter two cases, the tumors did not
respond to chemotherapy. Four patients (K-28, K54, K-68, and K-103) died at
home. Two (K-28 and K-103) showed no initial response to chemotherapy and
were discharged home in poor condition. One (K-54) had many recurrences and
died oftumor at home. K-68 showedgood initial response, wasdischargedhome,
and seen once in follow-up in good condition. Subsequent information from the
familyrevealedthatpatienthaddiedtwomonthslaterpresumably from recurrence.
Two patients died in hospital (K-45, K-75), K-75 died with recurrence and CNS
involvement. K-45 died with tumor recurrence.
Table IVgives a summary ofresponse to treatment and the number ofpatients
who had recurrence of tumor. With one exception (K-46) all patients who had484 J. C. WOSORN7U. F. K. NKRUMAH AND I. V. PERKINS
only an initial partial remission developed resistance to chemotherapv. There
was progression of the tumor in these patients.
LONG TERM SURVWORS
In this series, 15 out of 50 treated patients survived one year or longer (Table
1). There were 5 girIs and IO bovs, their ages ranging from 3 to II years. There
were ten Stage 1, two Stage II and three Stage III cases.
Of the ten Stage I long term survivors, the maxilla was involved in six, the
orbit was simultaneousl involved in onlv one ofthem. Other sites were mandible
in two and orbit in two. Four Stage I long term survivors had recurrent tumors.
sucessfiffly treated with chemotherapy. One of the Stage 11 long term surv-ivors
had involvement of right lower hd and left upper Ed. The tumor masses have
notchangedappreciablyin size withchemotherapy. There has been no recurrence
at other sites (survival tinoie as ofDecember 31, 1969 was 142 weeks). The other
Stage 11 patient had bilateral involvement of the orbits and mandibles and is
presently tumor fi-ee. Two oftheStage III cases have no recurren-es 123 and 109
weeks from date initial treatment was begun. One had extensive resection of
abdominal tumor; she also had unilateral mandibular, maxiBary and orbital
involvement. The second had complete remission with chemotherapy and is
stif tumor fi-ee. The third has had four recurrences and her central nervous
system is now involved.
Sixteen out of the 50 evaluable and treated patients were free of tumor as of
December 31, 1969. These included 13 patients with no tumor recurrence fonow-
ing initial treatment. Ofthese, seven were Stage 1. one Stage 11and three Stage
III patients. Two Stage I patients had one recurrence each and another Stage I
patient two recurrences. Five patients were ahve. but not considered tumor fi-ee
as of December 31, 1969. Thev include three Stage III patients, one Stage I
patient, and one Stage IV. All the Stage III patients had multiple recurrences.
One ofthem (K-64) has surv-ived over 104 weeks in spite of four recurrences.
DISCUSSIO'N
In this series of 60 histologicaRv proven cases of Burkitt's 'Lymphoma, the
estimatedlong term survival rate for 50 treated and evaluablepatients was 38-50/-i 0,
This overaR rate is higher than that of 21 O" reportedby Morrow et al. (I967) from
Uganda. Prognosis wa-s found to be related to the clinical stage of the disease at
presentation. This was especially true among the Stage I patients who did much
better than patients in aR other stages, and is in agreement with the experience of
the Kampala investigators (Morrow el al., 1967) who also found a much better
prognosis among Stage I patients. However, Stage I patients in this series, in
spite oftheir much betterprognosis compared with the other stages, did not do as
well as those reported from Uganda (Morrow et al., 1967). Prior to March 1969.
C.S.F. was examined only when neurological symptoms such a-s headaches.
neuropathv, convulsions or coma were present on admission or subsequently
developed. We now know that malignant pleocytosis of the C.S.F. can exist in
Burkitt's tumor patients in the absence of central nervous system symptoms.
The possibifity that a few of our Stage I patients were wrongly staged because of
this cannot be ruled out completely.BURKITT)S LYMPHOMA IN GHANA 485
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All our Stage I patients who died had large tumors with the orbit involved in
three, cervical lymph nodes in one and mandible extensively in another. The
relationship between gross orbital involvement and poor prognosis in the three
cases is not immediately obvious. However, such a relationship is suggested
from the three Stage I patients who had gross orbital involvement.
In the present series, Stage I and 11 patients (localized disease) made up
56% of the total group. In other comparable series, Stage I and 11 patients
comprised 32% (Moirrow et al., 1967) and 21% (Ziegler et al., 1969) of their total
groups. The higher percentage of patients with localized disease in our series
may well be due to understaging in patients who were evaluated prior to the
adoption of current staging procedures.
The calculated survival rate in our Stage III patients was better than that
reported by Morrow et al. (1967) from Uganda. This difference may be due to
the smaller number of ourStage IIIpatients (22) as compared to 38 in their series.
Whether surgical reduction of abdominal tumor masses influences survival
among Stage III patients, remains in our opinion unresolved. Ngu (1964) and
Morrow et al. (1967) reported that surgical reduction of abdominal tumor masses
appeared to improve the prognosis in Stage III patients. Two ofthe three Stage
III long term survivors in this series had ovarian masses excised. However, five
other patients who underwent unilateral or bilateral oophorectomies did not do so
well.
Age in our series, did not seem to influenceprognosis. This is at variance with
findingsby Morrow et al. (I967) who noted that in their series youngerpatients did
better than olderpatients.
The duration ofsymptoms fromreported date of onset to date first seen at any
medical facility, within a staging division, bore no relationship to prognosis.
This conforms with thefindings ofMorrow et al. (1967). However, the timeperiod
given by parents was difficult to verify, since there seemed to be a tendency by
parents to under estimate the duration ofsymptoms.
We aregrateful to Dr. Morrow andDr.Zieglerfor usefulsuggestions andadvice,
and to Mr. Greenberger and Mr. S. Briandt and his stafffor the illustrations. All
chemotherapeutic agents used in this study were supplied by the Cancer Therapy
EvaluationBranch,Chemotherapy,NationalCancerInstitute,Bethesda,Maryland.
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